Abel et al. have recently reported that melanoma cells adapt to RAF/MEK inhibitors through a FOXD3-mediated upregulation of ErbB3 transcription [28], which induced cell sensitization to the biological effect of exogenously added ErbB3 ligand neuregulin. This evidence concerns the gene MAP2K7 and melanoma.